209971-49-3

Basic information

• Product Name: 2,2,2-Trifluoro-N-(6-iodo...
• Synonyms: 2,2,2-Trifluoro-N-(6-iodo...;2,2,2-Trifluoro-N-(6-iodo-iMidazo[1,2-a]pyridin-2-yl)acetaMide;AcetaMide, 2,2,2-trifluoro-N-(6-iodoiMidazo[1,2-a]pyridin-2-yl)-
• CAS NO: 209971-49-3
• Molecular Formula: C₉H₅F₃IN₃O
• Molecular Weight: 355.0551796
• Mol File: 209971-49-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 245-246 °C
• Appearance: /
• Density: 2.09±0.1 g/cm3(Predicted)
• PKA: 0.98±0.46(Predicted)
• CAS DataBase Reference: 2,2,2-Trifluoro-N-(6-iodo...(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,2-Trifluoro-N-(6-iodo...(209971-49-3)
• EPA Substance Registry System: 2,2,2-Trifluoro-N-(6-iodo...(209971-49-3)

Safety Data

• Hazardous Substances Data: 209971-49-3(Hazardous Substances Data)

Usage

Description

2,2,2-Trifluoro-N-(6-iodo)benzenesulfonimidoyl)acetic acid, also known as TFBIAA, is a synthetic compound with a molecular formula of C8H5F3INNaO4S. It is a trifluoromethyl analog of SU11274, a potent and selective c-Met inhibitor. TFBIAA is recognized as a promising anticancer agent due to its ability to inhibit the c-Met signaling pathway, which plays a crucial role in the progression and metastasis of various types of cancer. The unique chemical structure and properties of TFBIAA make it a valuable tool for studying c-Met inhibition and for the development of novel cancer therapies.

Uses

Used in Pharmaceutical Industry:
TFBIAA is used as a therapeutic compound for targeted cancer treatment. Its primary application is in inhibiting the c-Met signaling pathway, which is implicated in the progression and metastasis of various cancers. By targeting this pathway, TFBIAA has the potential to offer a more precise and effective treatment approach for cancer patients.
Used in Cancer Research:
In the field of cancer research, TFBIAA serves as a valuable tool for studying the role of the c-Met signaling pathway in cancer development. Researchers can utilize TFBIAA to investigate the mechanisms of c-Met inhibition and to explore its potential synergistic effects with other therapeutic agents, thereby contributing to the advancement of cancer treatment strategies.
Used in Drug Development:
TFBIAA is also used in the development of novel cancer therapies. Its properties as a potent and selective c-Met inhibitor make it a promising candidate for the creation of new drugs that can target specific cancer pathways. The ongoing research and development of TFBIAA-based drugs aim to improve the efficacy and selectivity of cancer treatments, ultimately benefiting patients with various types of cancer.

Upstream product

• 407-25-0 trifluoroacetic anhydride 
• 209971-43-7 N-(5-iodopyridin-2-yl)-4-methylbenzenesulfonamide 
• 20511-12-0 2-amino-5-iodopyridine 
• 209971-43-7 N-(5-iodopyridin-2-yl)-4-methylbenzenesulfonamide 
• 209971-46-0 2-[5-iodo-2-{[(4-methylphenyl)sulfonyl]imino}pyridin-1(2H)-yl]acetamide 

Downstream Products

• 504413-29-0 N-{6-[(2-chloro-6-fluoro-phenyl)-hydroxy-methyl]-imidazo[1,2-a]pyridin-2-yl}-2,2,2-trifluoro-acetamide 
• 1213237-53-6 2,2,2-trifluoro-N-(6-(2-fluoro-5-methylbenzoyl)imidazo[1,2-a]pyridin-2-yl)acetamide 
• 1213237-52-5 2,2,2-trifluoro-N-(6-(3-fluoro-4-(trifluoromethyl)benzoyl)imidazo[1,2-a]pyridin-2-yl)acetamide 
• 1213237-54-7 2,2,2-trifluoro-N-(6-(2-fluoro-5-(trifluoromethyl)benzoyl)imidazo[1,2-a]pyridin-2-yl)acetamide 
• 1213237-51-4 2,2,2-trifluoro-N-(6-(3-fluoro-4-methylbenzoyl)imidazo[1,2-a]pyridin-2-yl)acetamide 
• 1213237-55-8 2,2,2-trifluoro-N-(6-(2-fluoro-4-(trifluoromethyl)benzoyl)imidazo[1,2-a]pyridin-2-yl)acetamide 
• 947248-49-9 6-iodoimidazo[1,2-a]pyridin-2-amine 
• 504413-39-2 N-[6-[(tert-butyl-dimethyl-silanyloxy)-(2-chloro-6-fluoro-phenyl)-methyl]-3-(2,6-difluoro-benzoyl)-imidazo[1,2-a]pyridin-2-yl]-2,2,2-trifluoro-acetamide 

Relevant articles and documents

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K

PI3 kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration and differentiation. The PI3 Kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations and PTEN p

6-Substituted 2-(N-trifluoroacetylamino)imidazopyridines induce cell cycle arrest and apoptosis in SK-LU-1 human cancer cell line

A series of 6-substituted 2-(N-trifluoroacetylamino)imidazopyridines have been synthesized and their bioactivities were evaluated. Compounds 6a, 6c, and 11a were the most active compounds with modest cytotoxic activity against six human cancer cell lines U251 (glioma), PC-3 (prostate), K-562 (leukemia), HCT-15 (colon), MCF7 (breast) and SK-LU-1 (lung). The cell cycle analysis showed that compounds 6a, 6c, and 11a induce a G2/M phase cell cycle arrest on SK-LU-1 cell line where inhibition of CDK-1 and CDK-2 may be implicated.

Chemoselective arylsulfenylation of 2-aminoimidazo[1,2-α]pyridines by phenyliodine(III) bis(trifiuoroacetate) (PIFA)

A series of 2-(trifluoroacetamido)imidazo[1,2-a]pyridines was prepared and treated with phenyliodine(III) bis(trifluoroacetate) (PIFA) in the presence of a variety of thiols leading chemoselectively to the corresponding 3-sulfides. Exposure of these adducts to silica gel in MeOH/CH2Cl2 provides a convenient method for the cleavage of the trifluoroacetamide group.